Clinical Trial Update: A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the safety and efficacy of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma not previously treated with systemic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Atezolizumab (Tecentriq) (atezolizumab)
• Bevacizumab (Avastin) (bevacizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Carcinoma, Hepatocellular | Phase 3 | Status: COMPLETED | Results posted: 2025-09-22